ABSI · Absci Corp · Webcasts, Transcripts & Audio
$8.45
-0.69 (-7.50%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Market Cap
$1.46B
Shares
172.75M
Volume · Nov 13
5.49M
Avg daily vol (3M)
3.84M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Absci Corp Webcasts
Earnings calls, investor updates, investor days and conferences for Absci Corp (ABSI), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-18
Absci Corp (ABSI) November 18, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-12
Absci Corp (ABSI) Q3 2026 Earnings Call
Revenue
$304,000
▼ 19.6% YoY Diluted EPS
$-0.19
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-16
Absci Corp (ABSI) September 16, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-15
Absci Corp (ABSI) September 15, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-11
Absci Corp (ABSI) Q2 2026 Earnings Call Transcript
Confident tone
ABS-201 Phase 1 interim data and PK profile
ABS-21 endometriosis program
Competitive landscape and standard of care
Revenue
$318,000
▼ 46.4% YoY Diluted EPS
$-0.21
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
Absci Corp (ABSI) June 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-03
Absci Corp (ABSI) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-07
Absci Corp (ABSI) Q1 2026 Earnings Call Transcript
Confident tone
ABS-201 androgenic alopecia (AGA) program
Pipeline expansion - prolactin / ABS-202
Endometriosis indication
Revenue
$215,000
▼ 81.8% YoY Diluted EPS
$-0.19
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-24
Absci Corp (ABSI) Q4 2025 Earnings Call Transcript
Confident tone
ABS-201 clinical progress
Androgenetic alopecia (AGA) opportunity
R&D efficiency
Revenue
$650,000*
▼ 2.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-12-11
Absci Corp (ABSI) Q3 2025 Earnings Call Transcript
Confident tone
ABS-101 phase one interim results and partnership decision
Pipeline reprioritization and capital discipline
ABS-301 immuno-oncology and other partnered programs
Revenue
$378,000
▼ 77.8% YoY Diluted EPS
$-0.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Absci Corp (ABSI) Q2 2025 Earnings Call Transcript
Confident tone
ABS-101 anti-TL1A clinical progress
ABS-201 androgenetic alopecia program
Almirall collaboration expansion
Revenue
$593,000
▼ 53.3% YoY Diluted EPS
$-0.24
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Absci Corp (ABSI) Q1 2025 Earnings Call Transcript
Confident tone
ABS-101 TL1A Clinical Milestone
ABS-201 Androgenic Alopecia Program
Business Development and Partnerships
Revenue
$1.18M
▲ 31.3% YoY Diluted EPS
$-0.21
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-18
Absci Corp (ABSI) Q4 2024 Earnings Call Transcript
Confident tone
ABS-101 anti-TL1A program
ABS-201 anti-prolactin receptor / androgenic alopecia
Pipeline and partner ecosystem growth
Revenue
$665,000*
▲ 96.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Absci Corp (ABSI) Q3 2024 Earnings Call Transcript
Confident tone
ABS-201 Dermatology Program
ABS-101 TL1A Program
R&D Day Catalyst
Revenue
$1.70M
▲ 128.6% YoY Diluted EPS
$-0.24
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Absci Corp (ABSI) Q2 2024 Earnings Call Transcript
Confident tone
New MSK Partnership
ABS-101 Anti-TL1A Program
Partnership Pipeline / Business Development
Revenue
$1.27M
▼ 62.3% YoY Diluted EPS
$-0.22
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
Absci Corp (ABSI) Q1 2024 Earnings Call Transcript
Confident tone
Platform efficiency and cost advantage
Internal pipeline progress
Partnerships and business development
Revenue
$898,000
▼ 29.2% YoY Diluted EPS
$-0.22
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-21
Absci Corp (ABSI) Q4 2023 Earnings Call
Revenue
$338,000*
▼ 78.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-14
Absci Corp (ABSI) Q3 2023 Earnings Call
Revenue
$744,000
▼ 68.6% YoY Diluted EPS
$-0.24
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-14
Absci Corp (ABSI) Q2 2023 Earnings Call
Revenue
$3.37M
▲ 236% YoY Diluted EPS
$-0.45
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-15
Absci Corp (ABSI) Q1 2023 Earnings Call
Revenue
$1.27M
▲ 54.9% YoY Diluted EPS
$-0.26
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-30
Absci Corp (ABSI) Q4 2022 Earnings Call
Revenue
$1.56M*
▲ 7.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Absci Corp (ABSI) Q3 2022 Earnings Call
Revenue
$2.37M
▲ 53.9% YoY Diluted EPS
$-0.30
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Absci Corp (ABSI) Q2 2022 Earnings Call
Revenue
$1.00M
▲ 37.6% YoY Diluted EPS
$-0.32
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-11
Absci Corp (ABSI) Q1 2022 Earnings Call
Revenue
$819,000
▼ 23% YoY Diluted EPS
$-0.33
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-22
Absci Corp (ABSI) Q4 2021 Earnings Call
Revenue
$1.45M*
Rev · 5q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Absci Corp (ABSI) Q3 2021 Earnings Call Transcript
Revenue
$1.54M
▲ 68% YoY Diluted EPS
$-0.33
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Showing 1–26 of 26 webcasts
Key facts
CIK
1672688
CUSIP
00091E109
13F (30d)
159 filings
144 filers
Visit website
Investor relations